Baker’s yeast is giving scientists a better understanding of drug interactions, which are a major cause of hospitalization and illness worldwide.
When two or more medications are taken at the same time, one can suppress or enhance the effectiveness of the other. Similarly, one drug may magnify the toxicity of another. These types of interactions are a major cause of illness and hospitalization. However, there are severe practical limits on the practical scope of drug studies in humans. Limits come in part from ethics and in part from the staggering expense. Because of the vast number of combinations of different drugs that might be prescribed together in the same patient, drug interactions in patients are not extensively studied, even in the process of reviewing new drugs for approval.
This limitation has caused researchers to turn to simpler model organisms in which to study drug interactions, enabling systematic study of drug interactions at relatively low cost, according toresearchers at the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital in Toronto. Dr. Frederick Roth and international colleagues published their findings after testing drugs on the simple yeast Saccharomyces cerevisiae, also known as brewer’s yeast or baker’s yeast.
“Baker’s yeast is a wonderful tool for this purpose,” says Dr. Roth. “Many aspects of both yeast and human genomes have remained the same since they diverged from a common ancestor around one billion years ago. When a specific combination of drugs has a surprising effect on yeast growth there is no guarantee that it will do the same thing to human cells. But it does give us a general idea of how often drugs are able to enhance or suppress each other’s effectiveness.” Dr. Roth is a Senior Investigator at the Lunenfeld-Tanenbaum and a Professor at the University of Toronto’s Donnelly Centre. He also holds a Canada Excellence Research Chair in Integrative Biology.
For this first test, the team worked with anti-fungal chemicals in a total of 440 drug pairs. They found that, in almost one fifth of the combinations, one drug reduced the effectiveness of the other drug. They also found that some drugs can have a greater tendency to suppress other drugs, while other drugs are more frequently suppressed. The same team published a related study in 2011, showing that for about one third of drug pairs tested the compounds increased each other’s effectiveness. “If drug interactions are happening at anything approaching these rates in humans, we should be very concerned,” Dr. Roth adds.
When one drug suppresses the effectiveness of another drug, “the patient is losing benefit from one or both drugs, while still potentially being exposed to their side effects,” Dr. Roth adds. When a drug combination has an effect that is more than the sum of its parts, the patient might get too much of a good thing, and it is possible for drugs to intensify each other’s toxicity as well.
“This methodology may also prove useful to explore positive types of drug interactions such as in personalized medicine,” adds Dr. Jim Woodgett, Director of the Lunenfeld-Tanenbaum. “Diseases such as cancer rarely respond to single medications, and this new systematic technological approach may have the potential to allow rapid optimization of combination therapies,” he notes. The study noted one example of a compound (Staurosporine) that was suppressed by acidity. This phenomenon is interesting in the context of cancer because the peculiar metabolism of cancer cells often makes the local tumour environment more acidic. It would be particularly exciting to find more anti-cancer compounds that were enhanced by acidity.